Capitaline

Corporate News 06-Jul-20

AstraZeneca Pharma India receives import and market permission for Dapagliflozin film coated tablet

From Drugs Controller General of India

AstraZeneca Pharma India has received Import and Market permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Dapagliflozin film coated tablet 10mg.

Dapagliflozin film coated tablet 10mg is additional indication in adults for the treatment of heart failure with reduced ejection fraction.

The receipt of this Import and Market permission paves way for launch of Dapagliflozin film coated tablet 10mg in India, subject to the receipt of related statutory approvals and licenses.

Previous News

Astrazeneca Pharma India fixes record date for interim dividend
( Market Beat - Reports 11-Aug-20 09:31 )

Astrazeneca Pharma India receives DCGI approval to import, market Selumetinib capsules
( Hot Pursuit - 27-Sep-21 09:37 )

Astrazeneca Pharma India standalone net profit rises 156.57% in the December 2022 quarter
( Results - Announcements 11-Feb-23 07:33 )

Astrazeneca Pharma India standalone net profit declines 45.75% in the December 2021 quarter
( Results - Announcements 09-Feb-22 08:13 )

Astrazeneca Pharma soars after receiving regulatory nod for importing Andexxa
( Hot Pursuit - 20-Jan-24 13:14 )

Board of Astrazeneca Pharma India recommends interim dividend
( Corporate News - 09-Aug-21 20:10 )

Astrazeneca Pharma India reports standalone net loss of Rs 2.88 crore in the March 2017 quarter
( Results - Announcements 10-May-17 13:41 )

Astrazeneca Pharma India standalone net profit rises 96.78% in the June 2022 quarter
( Results - Announcements 08-Aug-22 14:55 )

Astrazeneca Pharma India to hold board meeting
( Corporate News - 19-May-21 09:45 )

AstraZeneca moves up after reports of getting marketing nod for drug
( Hot Pursuit - 21-Jun-17 14:53 )

Astrazeneca Pharma India standalone net profit rises 84.08% in the December 2016 quarter
( Results - Announcements 03-Feb-17 14:16 )